Soo RA, de Marinis F, Han JY, Ho JC, et al. TARGET: A Phase II, Open-Label, Single-Arm Study of 5-Year Adjuvant Osimertinib in Completely Resected EGFR-Mutated Stage II to IIIB NSCLC Post Complete Surgical Resection. Clin Lung Cancer 2024;25:80-84.
PMID: 37914594